Inventor · disambiguated record
Ugur Eskiocak
Also filed as: ESKIOCAK UGUR
16 granted patents·10 pending applications·60 citations·filing 2013–2025
92Inventor score
Top patents by PatentIndex Score
26 records- 0196US10716851B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted Jul 21, 2020·10 cites·5 claims
- 0296US10350292B1Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2019·Granted Jul 16, 2019·12 cites·28 claims
- 0396US10279039B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted May 7, 2019·10 cites·20 claims
- 0496US10279038B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted May 7, 2019·11 cites·16 claims
- 0596US10279040B1Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted May 7, 2019·10 cites·20 claims
- 0695US10434175B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2019·Granted Oct 8, 2019·5 cites·20 claims
- 0787US2024181050A1Agonist antibodies that bind human cd137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2023·Application pending·0 cites
- 0885US11970538B2Multispecific binding constructs against checkpoint molecules and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2021·Granted Apr 30, 2024·1 cites·23 claims
- 0982US12503511B2Multispecific binding constructs against checkpoint molecules and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2024·Granted Dec 23, 2025·0 cites·16 claims
- 1080US12286483B2Method of treating cancer using CD137 antibodies and PD-1 antagonistsCOMPASS THERAPEUTICS LLC·Filed 2023·Granted Apr 29, 2025·0 cites·22 claims
- 1178US11046769B2Multispecific binding constructs against checkpoint molecules and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2019·Granted Jun 29, 2021·1 cites·22 claims
- 1278US2020046833A1Agonist antibodies that bind human cd137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2019·Application pending·0 cites
- 1375US11752207B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2020·Granted Sep 12, 2023·0 cites·13 claims
- 1470US11718679B2CD137 antibodies and PD-1 antagonists and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted Aug 8, 2023·0 cites·28 claims
- 1570US2025313645A1Cd137 antibodies and pd-1 antagonists and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2025·Application pending·0 cites
- 1664US9572828B2Treatment for melanomaUNIV TEXAS·Filed 2014·Granted Feb 21, 2017·0 cites·26 claims
- 1758US9561245B2Combination treatments for melanomaUNIV TEXAS·Filed 2013·Granted Feb 7, 2017·0 cites·19 claims
- 1858US2022306743A1Combination of ctla4 and pd1/pdl1 antibodies for treating cancerXILIO DEV INC·Filed 2022·Application pending·0 cites
- 1958US2022340662A1Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancerXILIO DEV INC·Filed 2022·Application pending·0 cites
- 2054US12280120B2Tumor-specific cleavable linkersXILIO DEV INC·Filed 2021·Granted Apr 22, 2025·0 cites·11 claims
- 2149US11851497B2CD137 antibodies and tumor antigen-targeting antibodies and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted Dec 26, 2023·0 cites·11 claims
- 2249US2023331799A1Masked il-15 cytokines and their cleavage productsXILIO DEV INC·Filed 2021·Application pending·0 cites
- 2349US2023159603A1Masked il-12 cytokines and their cleavage productsXILIO DEV INC·Filed 2021·Application pending·0 cites
- 2449US2023151072A1Masked il-2 cytokines and their cleavage productsXILIO DEV INC·Filed 2021·Application pending·0 cites
- 2547US2014080772A1Treatments for melanomaUNIV TEXAS·Filed 2013·Application pending·0 cites
- 2640US2017112865A1Treatment for melanomaUNIV TEXAS·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ugur Eskiocak files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →